肥厚型心肌病基因检测正常者亲属受累率低
该研究对基因检测正常的肥厚型心肌病(HCM)先证者亲属进行临床筛查,发现60%(270/453)先证者基因检测正常,其80%(751/938)亲属参与研究,基线时5%(34/751)确诊HCM,5年随访中0.3%(2/717)新发,受累亲属预后良好。
要点
- 基因检测正常的HCM先证者亲属中,基线HCM患病率为5%。
- 5年随访期间仅0.3%的亲属新发HCM,风险低。
- 受累亲属未发生不良疾病并发症,猝死风险低。
核心结论
- 对基因检测正常的HCM先证者进行系统家族筛查,受累亲属频率低且预后良好。
研究设计与样本
- 对连续且无亲缘关系的HCM先证者进行临床和基因检测,邀请未携带已知HCM基因致病/可能致病变异的先证者亲属参与临床检查。
主要发现
- 60%(270/453)的HCM先证者基因检测正常。
- 80%(751/938,中位年龄44岁)的亲属参与研究。
- 基线时5%(34/751)确诊HCM,5年随访期间0.3%(2/717)新发HCM。
- 受累亲属诊断时中位年龄57岁(IQR:51-70岁),三分之二(22/36)通过家族筛查诊断,三分之一(14/36)此前因症状、杂音或心电图异常诊断。
- 受累亲属均未发生不良疾病并发症,猝死风险低。
临床怎么用
- 对于基因检测正常的HCM先证者,其亲属仍应接受临床筛查,但受累概率低且预后较好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current guidelines recommend that relatives of index patients with hypertrophic cardiomyopathy (HCM) are offered clinical investigations to identify individuals at risk of adverse disease complications and sudden cardiac death. However, the value of family screening in relatives of index patients with a normal genetic investigation of recognized HCM genes is largely unknown. OBJECTIVES: The purpose of this study was to perform family screening among relatives of HCM index patients with a normal genetic investigation to establish the frequency of familial disease and the clinical characteristics of affected individuals. METHODS: Clinical and genetic investigations were performed in consecutive and unrelated HCM index patients. Relatives of index patients who did not carry pathogenic/likely pathogenic variants in recognized HCM genes were invited for clinical investigations. RESULTS: In total, 60% (270 of 453) of HCM index patients had a normal genetic investigation. A total of 80% of their relatives (751 of 938, median age 44 years) participated in the study. Of these, 5% (34 of 751) were diagnosed with HCM at baseline, whereas 0.3% (2 of 717 [751-34]) developed the condition during 5 years of follow-up. Their median age at diagnosis was 57 years (IQR: 51-70 years). Two-thirds (22 of 36) were diagnosed following family screening, whereas one-third (14 of 36) had been diagnosed previously because of cardiac symptoms, a murmur, or an abnormal electrocardiogram. None of the affected relatives experienced adverse disease complications. The risk of SCD was low. CONCLUSIONS: Systematic family screening of index patients with HCM and normal genetic investigations was associated with a low frequency of affected relatives who appeared to have a favorable prognosis.
引用
- Nielsen SK, Hansen FG, Rasmussen TB, et al. Patients With Hypertrophic Cardiomyopathy and Normal Genetic Investigations Have Few Affected Relatives. J Am Coll Cardiol. 2023. PMID: 37879779. doi:10.1016/j.jacc.2023.08.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。